Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07051044Recruiting
Cheek swab light test for lung cancer risk
This trial uses a simple cheek swab and a special light test to look for signs of lung cancer risk. It aims to help doctors decide who needs more testing, especially if you have symptoms or are currently being checked for lung cancer.
North ShieldsAges 18 years+ - NCT07054307RecruitingPhase 1
Study of MRG003 plus HX008 for EGFR-positive penile cancer
This trial tests two drugs, MRG003 and HX008, as a first treatment for men with EGFR-positive penile squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if the combination shrinks tumors or delays growth.
Chengdu, SichuanAges 18 years+ - NCT07054086Recruiting
Personalized treatment testing with tumor models for esophageal cancer
This trial tests whether a personalized treatment plan, chosen using a lab-grown model of your tumor, works better than standard therapy for esophageal cancer that can be surgically removed. It aims to find the most effective drugs for you before surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07052630Recruiting
Planning advance care after stem cell transplant
This study tests a program that helps stem cell transplant survivors plan their future care with their doctors. It uses a website and a patient navigator to guide you through conversations about your goals and values.
Seattle, WashingtonAges 18 years+ - NCT07051525Recruiting
Early vs. late stopping of antibiotics for fever in blood cancer treatment
This trial compares stopping antibiotics early (after fever resolves) versus continuing them as usual in adults with blood cancers who develop fever during treatment. It aims to find the best timing to reduce unnecessary antibiotic use.
Melbourne, VictoriaAges 18 years+ - NCT07053059RecruitingPhase 2
CAR T-cell therapy to prevent relapse in high-risk B-cell ALL
This trial tests a new CAR T-cell therapy (obecabtagene autoleucel) given as a consolidation treatment after initial remission to prevent relapse in people with high-risk B-cell ALL. It's for patients who have achieved first remission but still have high-risk features in their leukemia.
Houston, TexasAges 18 years+ - NCT07047183RecruitingPhase 2
A study of venetoclax and azacitidine before stem cell transplant for MDS
This trial tests a combination of two drugs (venetoclax and azacitidine) given before a stem cell transplant to see if it improves outcomes for people with a certain type of myelodysplastic syndromes (MDS) that is higher risk. If you have higher-risk MDS and are planning a stem cell transplant, this may be an option.
Changchun, JilinAges 18 years+ - NCT07053254Recruiting
Studying vein grafts in older heart bypass patients
This trial looks at how vein grafts work in older adults who need coronary artery bypass surgery. It aims to understand why grafts sometimes fail, so doctors can improve treatment.
SeoulAges 19–100 - NCT07052669RecruitingPhase 3
Shorter Chemo-Radiation Plus Immunotherapy for Stage III Lung Cancer
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07041801RecruitingPhase 1/Phase 2
Stem cell therapy for lupus patients
This trial tests whether a type of stem cell from umbilical cords can help people with systemic lupus erythematosus (an autoimmune disease). It aims to find a new way to reduce lupus symptoms and improve quality of life.
Shenzhen, GuangdongAges 18–65 - NCT07041099RecruitingPhase 1
Study of CLN-978 for Sjögren's disease
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that helps your immune system target and destroy disease-causing B cells. It's for people with moderate to severe Sjögren's disease who haven't had success with other treatments.
Orlando, FloridaAges 18 years+ - NCT07039994Recruiting
Early palliative care for advanced lung cancer using an e-health system
This study tests whether an online platform can help deliver early palliative care to people with advanced lung cancer. The goal is to see if this approach can improve quality of life and manage symptoms from the start of treatment.
Badalona, BarcelonaAges 18 years+ - NCT07037732Recruiting
Monitoring rituximab in autoimmune diseases
This study looks at the levels of rituximab (a medicine that calms the immune system) and your body's response to it in people with certain autoimmune diseases. It may help doctors understand how to better adjust treatment.
Nice, Alpes MaritimesAges 18 years+ - NCT07039656RecruitingPhase 2
Toripalimab plus chemo after NSCLC surgery
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
Guangzhou, GuangdongAges 18–75 - NCT07035002RecruitingPhase 1
PD-1 knockout TILs for advanced colorectal cancer
This trial tests a new therapy where immune cells (TILs) from your tumor are modified to fight cancer more effectively. It's for people with advanced colorectal cancer who can't get standard treatments.
Shanghai, None SelectedAges 18–70 - NCT07041320Recruiting
Oral chemo and immunotherapy for older adults with lung cancer
This trial is testing a combination of an oral chemotherapy pill (vinorelbine) and an immunotherapy drug (PD-1 inhibitor) for people aged 65 and older with advanced non-small cell lung cancer who have not had treatment before. The goal is to see if this approach can help control the cancer with fewer side effects.
Hefei, AnhuiAges 65 years+ - NCT07035626RecruitingPhase 1/Phase 2
Spermidine to prevent dry mouth from radiation therapy
This trial tests whether spermidine (a natural compound) can help prevent dry mouth caused by radiation treatment for head and neck cancer. It is for patients who will receive a significant dose of radiation to their saliva glands.
Chengdu, SichuanAges 18–80 - NCT07038733Recruiting
Lymph node study for kidney cancer patients
This study looks at lymph nodes in people with known or suspected kidney cancer to learn more about the disease. It may help researchers understand how kidney cancer affects the lymph system.
New Haven, ConnecticutAges 18 years+ - NCT07035938Recruiting
T-Cell Health in Blood Cancer Patients Study
This study looks at how T-cells (a type of immune cell) work in people with certain blood cancers (B-cell lymphoma or multiple myeloma) compared to healthy volunteers. The goal is to learn more about the immune system in these cancers, which may help improve future treatments.
Xiamen, FujianAges 18 years+ - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT04691284Recruiting
Test how the gut microbiome changes during major cancer treatment
This study looks at your gut “microbiome” (the bacteria in your intestines) while you receive high-dose chemotherapy and a stem cell transplant, or CAR-T cell therapy. Researchers hope to understand how these treatments affect the microbiome, which may relate to how well patients do.
Bratislava, SlovakiaAges 18 years+ - NCT06598527RecruitingPhase 3
Radiation and immunotherapy before surgery for lung cancer
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
Guangzhou, GuangdongAges 18–75 - NCT06720818Recruiting
Infection-fighting cells in severe lung injury
This study looks at a type of immune cell (MAIT cell) in patients with severe lung problems caused by infections, pancreatitis, head injury, burns, or major surgery. It aims to understand how these cells change during illness, which may lead to better treatments.
ToursAges 18 years+ - NCT07029958RecruitingPhase 4
Transplant protocol for EBV-related T/NK lymphoproliferative disease
This trial tests a stronger transplant conditioning regimen to treat a rare immune disorder caused by the Epstein-Barr virus. It aims to improve outcomes and reduce a complication called graft-versus-host disease, where donor cells attack the patient's body.
BeijingAges birth–18 years
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,550 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.